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Abstract
Background: Congenital adrenal hyperplasia is a rare autosomal recessive disorder
where the mutation in P450 family 17 subfamily A member 1 gene (CYP17A1) is involved
in its etiology. The disorder represents itself with low blood levels of estrogens,
androgens, and cortisol that generally couples with hypertension, Hypokalemia, sexual
primary amenorrhea, infantilism and in affected individuals.
Case: In this study, the CYP17A1 gene in a 14-year-old female was examined. The
karyotype of the patient was 46, XX, and the analysis of the CYP17A1 gene by Sanger
sequencing revealed a novel homozygous deletion c.1052-1054CCT which led to
isolated 17,20-lyase deficiency.
Conclusion: In conclusion, this study report an in-frame deletion which results in
isolated 17, 20-lyase deficiency, and the mutation might be used for diagnosis in other
patients with distinctive clinical symptoms.
Key words: Congenital adrenal hyperplasia (CAH), CYP17A1 gene, Ambiguous
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1. Introduction
Congenital adrenal hyperplasia (CAH) is a group
of rare disorders demonstrated by a failure in one
of the five enzymes responsible for cortisol produc-
tion in autosomal recessive pattern (1). In adrenal
glands, Pregnenolone is made from cholesterol
which later can be processed to either mineralo-
corticoids or glucocorticoids or to sex steroids in
adrenals and gonads (2).
The p450c17 enzyme is encoded by theCYP17A1
gene located on 10q24.3 (3) and spans 6.6 kb,
which comprises eight exons (4). ”This gene tran-
scribes 2.1-kb mRNA molecule, which expresses
in both the adrenals and gonads and generates a
57-kDa microsomal cytochrome P450c17 enzyme.
The CYP17A1 enzyme catalyzes both steroid 17-
hydroxylase and 17,20-lyase activities” (5). Enzy-
matic failure of the P450c17 enzyme leads to
both glucocorticoids and sex steroids deficiencies.
After a reduction in blood glucocorticoids levels
due to P450c17 defect, anterior pituitary tries to
compensate for the insufficiency of glucocorticoids
levels by producing extra Adrenocorticotropic hor-
mone (ACTH). This results in the extra generation
of steroid precursors and elevated ACTH level,
which leads to some Congenital adrenal hyper-
plasia and result in hypertension, hypokalemia,
and a suppressed renin-angiotensin system (6, 7).
Moreover, due to the impairments in CYP17A1, the
mineralocorticoid precursors (corticosterone and
11-deoxycorticosterone) accumulate, which demon-
strate glucocorticoid activity, therefore defect in
P450c17 does not associate with adrenal crisis,
rather than other CAH variants (8). Mutations in
the CYP17A1 gene are the rarest defects in CAH
that yields to steroid 17-hydroxylase and 17,20-
lyase deficiencies (9). Several mutations in the
CYP17 gene have been reported that cause either
complete or combined17-hydroxylase/17,20-lyase
or isolated 17, 20-lyase enzyme deficiencies (10-
14).
The purpose of this study was to investigate
the molecular defects in CYP17A1 gene and its
relationship with Congenital adrenal hyperplasia.
2. Case presentation
A 14-year-old female, the first child of con-
sanguineous parents with normal family history
was referred to the genetic clinic with high blood
pressure, ambiguous genitalia, and lack of pubertal
development. The blood sample was taken after
receiving written informed consent from her par-
ents. No pubic or axillary hair was seen by physical
examination, and she had no clinical symptoms
of Turner syndrome with 46, XX karyotype. In
the sonographic survey, uterus was infantile. She
was hypertensive (150/90 mmHg, 50th percentile
for age) with high gonadotropins levels (LH, 19
mU/mL; FSH, 34 mU/mL). Moreover, low peripheral
concentrations of sex steroids were seen (Table I).
2.1. Sequencing of CYP17A1 gene
Genomic DNA was purified from peripheral
blood leukocytes (PBL) using QIAGEN Mini Blood
kit. All the exons of CYP17A1 genewere pro-
liferated by PCR (primers listed in Table II),
which were designed with Primer3 software (http:
//primer3.sourceforge.net). All the PCR products
were sequenced in both directions by sanger
sequencing.
2.2. Mutational analysis
As shown in Figure 1, a new in-frame homozy-
gous deletion c.1052-1054CCT in exon 6 was
identified that reported for the first time. 17α-
hydroxylase deficiency was first pronounced by
Biglieri and colleagues (15), who was phenotypi-
cally female and presented with sexual infantilism,
primary amenorrhea and hypertension.
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Table I. Clinical and hormonal characteristics
Blood pressure (mmHg) 150/90
Karyotype 46,XX
Tanner stage (breast/pubic hair) B1P1
ACTH (0-60 pg/mL) 76
Cortisol (5-25 μg/dL) 17
LH (Female, 12-18 yr: 0.1-10 mU/mL) 19
FSH (Female, 12-18 yr: 0.3-9 mU/mL) 34
Estradiol (30-120 pg/mL) 15
DHEA (350-4300 ng/mL) 52
Progesterone (0.1-1.3 ng/mL) 4.6
Table II. Primers for CYP17A1 amplification
Exon Primers Sequences (5’-3’) Areas Product size (bp)
1 1F CACTGCTGTCTATCTTGCC 1802-2277 476
1R CCTTCACATCATCCCACTA
2 2F AGGGACCAGAGGTGTAAG 3730-4070 341
2R GCAGCAGTAGCCAAGAA
3 3F AGGGTGCTGATTCATTTC 4132-4544 413
3R GCAGAGGAGGTAGAGGTG
4 4F CGCTTGATGTTTGATTGA 4819-5214 396
4R CACCCTGCTCTTGTGATT
5 5F ACAGAAGTATGGCAGGAGT 5776-6289 514
5R CCAGAGTAGGTTGGAGGT
6 6F ACTGGGAAGGGACTGGA 6182-6496 315
6R GGCTAGATGTCACTGGGAG
7 7F AGTGGGAATGAGGGAGTA 7244-7599 356
7R GTCAACAGGTCGGTATAGTT
8 8F TCAACCAGGGCAGAACC 7914-8359 446
8R GGAAGAATGGCGGAGAA
F: Forward R: Reverse
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Figure 1. (A) Schematic representation of CYP17A1 gene location on chr.10.
(B) Sanger sequence chromatogram of the CYP17A1 gene show three nucleotide deletion position 1552–1554 within exon 6
(deletion of 351Leu in protein and CCT deletion on cDNA sequence).
3. Discussion
17α-hydroxylase and 17, 20-lyase deficiencies
are rare types of CAH which make up ∼1% of
all CAH patients (16). ”In general, the majority of
patients with CAH present with hypertension and
primary gonadal failure during adolescence and
adulthood, however, a few individuals are reported
to be normotensive at the time of diagnosis” (7, 9).
The deficiency of 17a-hydroxylase is a rare reason
of CAH, with little more than 100 cases reported
(17). 17α-hydroxylase deficiency was first described
in a 35-year-old patient in 1966 by Biglieri and
co-workers, who was phenotypically female and
presented with hypertension, sexual infantilism,
and primary amenorrhea. In the complete defi-
ciency of CYP17A1(CDC), the hormonal alterations
are summed up as sex steroids and cortisol insuf-
ficiencies with mineralocorticoids excessiveness.
All afflicted individuals were born with sexual
infantilism and incapable of secondary sexual
characteristics development (18). Isolated 17,20-
lyase deficiency (ILD) was first described in boys
with a disorder of sex development (DSD) (11,
19). In addition to CYP17A1gene, mutations in its
redox partner POR gene, which encodes protein
P450 oxidoreductase, can eliminate the 17,20-
lyase activity (ILD) of CYP17A1, which is character-
ized by abnormal sexual development and hyper-
tension (20). lastly, the purest form of ILD results
from defects in the CYB5A gene (21), encoding the
allosteric activator b5, which selectively give rise
to the ILD. These individuals maintain a hint of ILD,
about 10% of normal, which leads to DSD in 46, XY
males.
Symptoms can be briefly listed as hypertension,
primary amenorrhea, and ambiguous genitalia. In
this case, unlike CDC, the levels of most 17-
hydroxysteroids were elevated, suggesting exclu-
sive impairment of ILD. Moreover, the level of
cortisol as opposed to in CDC patients exists
in the normal range which further rules out the
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impairment of 17-hydroxylase activity. The alter-
ation in 351Leu which lies in the redox partner-
binding domain of P450c17 leads to an impairment
in lyase activity of P450c17 (14, 19), in other words,
disrupt interactions of redox partner proteins with
CYP17A1.
In sum, this case manifested typical feature of
17α-hydroxylase and 17,20-lyase deficiencies (e.g.,
hypertension and ambiguous genitalia). This study
is the first paper to report an in-frame deletion
which results in isolated 17, 20-lyase deficiency,
and this mutation might be used for diagnosis in
other patients with distinctive clinical symptoms.
Identification of 17α-hydroxylase/17,20 lyase defi-
ciency was confirmed by the particular profile of
adrenal steroid levels, and further confirmation by
CYP17A mutation analysis.
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